The UK has the researchers, the clinics, and the customers. The biggest rounds have gone to a Swedish company and an American one, and Abu Dhabi has bought into a British one.
UK longevity has had a year of huge numbers, and few of them carry a UK address.
In July, Neko Health, the Swedish company co-founded by Spotify's Daniel Ek, announced a $700 million Series C to open its first clinic in New York, having built a UK business across London, Manchester and Birmingham.
Then in October, the British Society for Research on Ageing (BSRA), whose membership has tripled since 2022 to around 300, made a far smaller request of the industry, which was a little money for young scientists working at more than fifty British institutions.
The gap between those two announcements holds the story we want to examine.
The UK has a research base that produces the fourth-largest volume of geroscience papers in the world, and it has customers willing to pay £299 for a scan that looks for early signs of disease.
What it shows less clearly is a funding chain that connects the one to the other.
A note on scope before we go any further, much of what is sold as UK age tech serves people who are already older, from home monitoring to care-home software, and that market deserves an examination of its own.
This piece concerns itself with two other groups, which are the companies trying to change how ageing works at a cellular level and the businesses selling prevention to people who are not yet ill.
Why UK longevity begins with a gap in healthy years
The demographic case is familiar, though the numbers repay a second look.
The UK population aged 85 and over is projected to double to 2.6 million over two decades, and the average time spent in poor health rose from 10.3 to 11.3 years between 2000 and 2019.
Those years are very unevenly shared.
In the most deprived areas of England, healthy life expectancy at birth is 49.8 years for men and 48.2 for women, and in the least deprived areas it is 69.2 and 68.5, a difference of about twenty years.
The UK also trails on the measure of longevity; companies say they exist to improve.
The UK ranks 14th in the International Longevity Centre's Healthy Ageing and Prevention Index, with a healthspan of 70.5 years against 74.4 in Japan and 72.3 in Sweden on 2022 data.
Geroscience, the study of how the biology of ageing drives several diseases at once, is where the UK's academic strength lies: the UK produces the fourth-largest volume of research papers in the field and hosts around 7 per cent of its companies.
The Royal Society has suggested a tenfold increase in spending on ageing research, to roughly £300 million a year, because one estimate puts the present figure at 0.049 per cent of the £63 billion that ageing costs the country annually.
The equivalent American body, the National Institute on Ageing, is funded at $4.4 billion.
Cambridge is turning cellular rejuvenation into companies.
The Cambridge biotech cluster shows the academic strength most clearly, and it shows up in the seed rounds.
Shift Bioscience, founded in 2017 and led by Dr Daniel Ives, who previously spent three years at the Francis Crick Institute, raised $16 million in October 2024 in a round led by BGF, with F-Prime Capital, Kindred Capital and the Abcam founder Jonathan Milner taking part.
Its virtual cell combines generative AI with a biological ageing clock to predict which sets of genes might safely rejuvenate cells, and Lord David Prior, formerly chairman of NHS England, became its chair in 2025, joined by Sir Tony Kouzarides of the Milner Therapeutics Institute as scientific adviser.
"…bring cell rejuvenation therapeutics closer towards clinical trial." — Dr Daniel Ives, CEO, Shift Bioscience
clock.bio works from the Milner Therapeutics Institute at the University of Cambridge, it's a $5.3 million seed round, led by LocalGlobe in the same month as Shift's, funded an Atlas of Rejuvenation Factors, a catalogue of more than 100 genes tied to the way stem cells rejuvenate themselves, found through genome-wide CRISPR screens, and Milner invested there too. The pattern across both rounds is a handful of specialist investors and one founder-turned-investor who appears in each.
The largest commitment to the same territory came from a company that launched in the United States and the United Kingdom together.
Altos Labs, dedicated to the biology of cellular rejuvenation, launched in 2022 with $3 billion in commitments and a Cambridge institute led by Wolf Reik, a pioneer of epigenetic reprogramming who had directed the Babraham Institute. Britain supplied the scientist and a site.
Where the money for UK longevity actually comes from
Set against that, the year's financing looks a bit lopsided.
Longevity rounds tracked so far in 2026 total $1.9 billion across 43 financings, more than double the same period of 2025, yet a Swedish scanning business and an American reprogramming company, Neko Health and NewLimit, account for about 59 per cent of it.
European deal counts rose from four to twelve, but European capital outside Neko comes to roughly $172 million, below last year's comparable figure.
Shift's $16 million is roughly one twenty-seventh of the $435 million NewLimit raised in a single Series C in June. Capital from further afield has also found British companies: Abu Dhabi's M42 took a stake in Juvenescence in 2025 that valued the UK-based company at just over $550 million, as part of a Series B-1 whose first tranche raised $76 million. British public capital appears as well, though later and for a different kind of product.
The British Business Bank co-led an $85 million Series B in January 2026 for Tenpoint Therapeutics, a London and Seattle company whose newly FDA-approved product is an eye drop for presbyopia, the age-related loss of near vision. Whether that belongs under longevity depends on how generously the word is used.
Money for the research beneath those companies has separated from money for the companies themselves. The BSRA held its 75th annual scientific meeting in September with more international and industry delegates than ever, and one of its trustees describes funding as the main thing holding back its early-career scientists, even as innovation in longevity supplements and functional foods grows.
"the money being made is not making its way back to academia" — Professor David Weinkove, Durham University, emeritus chair and trustee, BSRA
The regulatory frame adds friction.
The MHRA, like other regulators, does not recognise ageing itself as a disease indication, so a drug cannot be authorised simply for slowing ageing, and trials must either pick a disease endpoint or wait for biomarkers of ageing to be accepted as stand-ins, something with no agreed method of validation yet.
This is also where UK age tech and longevity biotech part ways.
A care-home risk tool can be sold to a care provider today; a therapy aimed at ageing cannot be sold to anyone until a regulator accepts what it is for, and without that acceptance insurers are reluctant to cover it.
What the consumer side of the market is selling
Preventive health is where the paying customers are.
Neko Health charges £299 in the UK for a 60-minute scan covering skin health and markers linked to prediabetes, metabolic syndrome, stroke and heart attack risk, and says more than 100,000 people across the UK and Sweden have taken one, with more than 350,000 registered or waiting.
About three-quarters of members book and prepay their next annual scan before leaving, and the company reports statistically significant improvement in five of seven key markers between a member's first and second scans.
Some clinicians question whether whole-body scans find enough real disease to justify the cost and the false alarms they can produce.
"…a completely new healthcare experience designed to keep people healthy, catch problems early…" — Hjalmar Nilsonne, co-founder and CEO, Neko
At the other end of the market, HOOKE London, a Mayfair clinic founded in 2023, reports memberships of up to £54,000 a year and one-off diagnostic days of up to £15,000, bundling full-body MRI, a CT heart scan, VO2 max testing and blood work covering almost seventy biomarkers. Its average member is now around 45, younger than the fifties it was first expected.
Biological age tests are a different product with a different problem.
Whether built on epigenetic clocks or on other markers such as telomeres, they are often presented as definitive scores, yet their precision and clinical usefulness remain under debate, and there is no consensus on how biomarkers of ageing should be validated before they reach the clinic.
A biological age test can give a customer a number, and what that number means for treatment is a question regulators have not settled.
Advertising regulators have started to police the claims, though no regulator recognises ageing as the condition being treated.
The Advertising Standards Authority (ASA) has pursued health claims in this territory too, including a May campaign that told Londoners eating pecans would help them live longer and, in July, an advertiser's unauthorised longevity and anti-ageing claims for coffee.
What UK longevity still has to answer
None of this settles whether UK longevity is a place where companies are built or only where they begin.
Shift has also set up facilities in North America; Altos's Cambridge institute sits inside a company that launched in two countries at once, and Neko's next clinic is in New York.
Each can be explained by commercial logic, and together they raise the question of how much of the value created from British science will stay in Britain.
We think the questions worth putting to founders and investors are these.
If a £299 scan is the product that scales, does any of the revenue reach the research behind it?
If a biological age test result cannot yet be tied to a treatment, who decides what it is for?
If cellular rejuvenation reaches trials and a regulator eventually accepts ageing as an indication, will the companies positioned to benefit still be British?
And with roughly twenty years separating healthy life expectancy in England's most and least deprived areas, which of UK longevity's customers are being served first?
Editorial note
This piece is purely based on secondary research, we have not yet spoken to the companies named here and would welcome the chance to.
If you are building, researching or backing a company in UK longevity, we would really appreciate your opinions at [email protected] .
Also read: Employer National Insurance: What UK Startups Pay in 2026
Sources: Royal Society, Increasing healthy life expectancy: the policy implications of geroscience (May 2024) · ONS, Healthy life expectancy by national area deprivation, England and Wales (2022 to 2024) · The King's Fund and ILC, national mission for ageing (8 Jun 2026; initiated and funded by Daiichi Sankyo) · NutraIngredients, BSRA feature (5 Oct 2026) · New Market Pitch, longevity funding trends (updated 22 Sep 2026) · Neko Health Series C announcement (15 Jul 2026); The Next Web · Shift Bioscience releases via Business Wire, Cambridge Network and UKTN; Taylor Wessing · clock.bio release via Business Wire; GenomeWeb · Altos Labs launch release (2022); MIT Technology Review · M42 via WAM (16 Apr 2025); Enterprise · Seedtable (Juvenescence Series B-1) · Tenpoint Therapeutics via Business Wire (28 Jan 2026) · Spear's, HOOKE London · Aging, longevity clinics review · NutraIngredients on the ASA rulings · Marketing Stockport, Greater Manchester study.
